15.03.2012 - Foodborne bacteria such as Salmonella and Campylobacter are becoming more and more resistant to antimicrobial drugs, according to a joint report published by the European food watchdog EFSA and the European Centre for Disease Prevention and Control (ECDC).
High resistance levels were recorded to ampicillin, tetracyclins and sulfonamides in Salmonella isolates from humans (13%-75%), whereas resistance to third-generation cephalosporins and fluoroquinolones remained low (0.2%-7%). In Campylobacter isolates from human cases, resistance to ampicillin, ciprofloxacin, nalidicic acid, and tetracyclins were high (21%-84%), while resistance to erythromycin was recorded at low to moderate levels (0.5%-25%). Most resistances are transmitted by meat consumption from animals that have become resistant to antibiotics, according to the „EU report on antimicrobial resistnce in zoonotic bacteria affecting humans, animals, and foods.“ The highest occurrence to ciproflaxin was noted in Salmonella from turkeys (28%) followed by fowl and broiler meat (24%). High resistance, ranging from 37% to 84% was also observed in Campylobacter isolates from fowl, pigs, and cattle. Methcillin-resistant Staphylococcus aureus (MRSA) in food and animals occurred at levels varying from 0% to 79%, and was most commonly found in turkeys. The surveillance data, which form the base of the report, were submitted in 2010 by 26 EU member states.
26.11.2015 Bioeconomy movers and shakers from every corner of the globe met this week at the world’s first Global Bioeconomy Summit in Berlin to discuss, debate and define better ways to ensure the bioeconomy succeeds on an international level.
24.11.2015 After weeks of speculation it is official: US pharma major Pfizer and Irish Botox maker Allergan will merge. With the deal, Pfizer is planning to dodge the high US taxes, causing indignation among US politicians.
23.11.2015 Amidst talk of the IPO window closing and cancelled flotations, diagnostics firms are still striking a chord with investors. Swedish Immunovia and German Curetis are successfully raising public money.
17.11.2015 The first Italian accelerator specifically for biotech projects has been launched with help from Sofinnova Partners. The plan of BiovelocITA: to help Italy grow into one of Europe’s strongest biotech markets.
13.11.2015 Scientists in Bath, UK, have developed a medical dressing that turns fluorescent green when it detects infection. The researchers hope that the smart burns dressing will help fight antibiotic resistance.
13.11.2015 Out with the old: Roche is discarding four sites with 1,200 staff in an effort to restructure its manufacturing network for small molecules. Instead, a new manufacturing site will be built in Switzerland.
10.11.2015 Algae have many skills, but cancer fighting was not one of them – until now. Researchers from Australia and Germany have genetically engineered diatom algae to accurately deliver chemotherapeutic drugs.
10.11.2015 AstraZeneca has plucked Californian biopharma company ZS Pharma from under Actelion’s nose. The UK company is paying US$2.7bn (€2.5bn) to acquire ZS and its promising hyperkalaemia treatment currently under US regulatory review.